Gassia J P, Durand D, Ton That H, Degroc F, Suc J M
Proc Eur Dial Transplant Assoc. 1980;17:719-24.
We report the use of the orally active converting enzyme inhibitor Captopril in hypertensive patients with mild chronic renal failure. Twenty eight patients were followed for a period of six months. Eleven patients required the addition of furosemide. Mean arterial pressure (MAP) decreased in all but two at six months (MAP: 102 +/- 0.8 vs 133 +/- 2.2mmHg, p less than 0.001). Untoward effects were frequent: the commonest reactions are loss of taste (four patients), skin rashes (11 patients), proteinuria (2 patients), tachycardia (2 cases). These side effects disappeared after reduction of dose (10 cases) or withdrawal (8 cases). Patients on 300mg daily or less were free of any untoward effect. In summary (i) Captopril alone or in combination with furosemide has an antihypertensive effect in patients with chronic renal failure and hypertension; (ii) side effects seem to be dose dependant and a reduced dosage should be used in these patients.
我们报告了口服活性转化酶抑制剂卡托普利在轻度慢性肾衰竭高血压患者中的应用。28例患者随访了6个月。11例患者需要加用呋塞米。除2例患者外,其余患者6个月时平均动脉压(MAP)均下降(MAP:102±0.8 vs 133±2.2mmHg,p<0.001)。不良反应很常见:最常见的反应是味觉丧失(4例)、皮疹(11例)、蛋白尿(2例)、心动过速(2例)。这些副作用在减量(10例)或停药(8例)后消失。每日服用300mg或更少剂量的患者没有任何不良反应。总之,(i)卡托普利单独使用或与呋塞米联合使用对慢性肾衰竭合并高血压患者有降压作用;(ii)副作用似乎与剂量有关,这些患者应使用较低剂量。